Cantor Fitzgerald Weighs in on ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, June 5th. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will earn $0.51 per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share.

Other research analysts have also recently issued reports about the stock. Bank of America increased their price target on shares of ACADIA Pharmaceuticals from $18.00 to $23.00 and gave the stock a "hold" rating in a report on Thursday. HC Wainwright upped their price target on shares of ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the company a "buy" rating in a report on Monday, May 19th. Needham & Company LLC boosted their price target on ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, May 19th. JPMorgan Chase & Co. lifted their price objective on ACADIA Pharmaceuticals from $26.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Wall Street Zen upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Six investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $26.79.

ACADIA Pharmaceuticals Stock Up 1.5%

NASDAQ:ACAD traded up $0.32 during midday trading on Monday, reaching $22.30. The stock had a trading volume of 1,454,077 shares, compared to its average volume of 1,939,115. The stock has a market cap of $3.73 billion, a P/E ratio of 28.59 and a beta of 0.65. The firm has a fifty day simple moving average of $17.36 and a two-hundred day simple moving average of $17.66. ACADIA Pharmaceuticals has a 12-month low of $13.40 and a 12-month high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company had revenue of $244.32 million for the quarter, compared to analysts' expectations of $239.32 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. ACADIA Pharmaceuticals's revenue for the quarter was up 18.7% compared to the same quarter last year.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, Director Laura Brege sold 14,446 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the sale, the director now directly owns 15,095 shares in the company, valued at $328,769.10. This trade represents a 48.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mark C. Schneyer sold 3,498 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $14.60, for a total value of $51,070.80. Following the completion of the transaction, the executive vice president now directly owns 62,773 shares of the company's stock, valued at approximately $916,485.80. The trade was a 5.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,273 shares of company stock valued at $653,182 in the last quarter. Corporate insiders own 26.50% of the company's stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in ACADIA Pharmaceuticals by 9.0% during the 1st quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company's stock worth $252,526,000 after acquiring an additional 1,255,594 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at about $60,845,000. Fred Alger Management LLC lifted its stake in shares of ACADIA Pharmaceuticals by 2.0% in the first quarter. Fred Alger Management LLC now owns 2,769,828 shares of the biopharmaceutical company's stock worth $46,007,000 after acquiring an additional 54,899 shares during the period. First Trust Advisors LP boosted its holdings in ACADIA Pharmaceuticals by 27.0% in the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company's stock valued at $49,547,000 after acquiring an additional 574,251 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in ACADIA Pharmaceuticals during the 4th quarter valued at approximately $40,935,000. 96.71% of the stock is currently owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.